Precision Medicine Market Revolution 2025: From Genomic Mapping to AI-Driven Treatment Strategies

Precision Medicine Market reached US$98.87 billion in 2024 and is expected to reach US$329.73 billion by 2033, growing at a CAGR of 14.8% during the forecast period of 2025-2033.

DataM Intelligence has published a new research report on "Precision Medicine Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/precision-medicine-market?oppratik

Mergers and Acquisitions (2025)

AbbVie acquired Gilgamesh Pharmaceuticals' Bretisilocin in a deal worth up to USD 1.2 billion, expanding its portfolio of next-generation depression therapies.

Gilead Sciences' Kite bought Interius BioTherapeutics for USD 350 million to enhance its in vivo CAR-T therapy platform, a major step beyond conventional ex vivo approaches.

MannKind Corporation acquired scPharmaceuticals for USD 360 million, adding the FUROSCIX on-body infuser for heart failure and kidney disease to its portfolio.

CorMedix purchased Melinta Therapeutics for USD 300 million, strengthening its infectious disease portfolio.

Aurobindo Pharma acquired Lannett Company for USD 250 million, boosting its U.S. manufacturing and generics operations.

Tempus AI bought Paige for USD 81.25 million, integrating AI-driven digital pathology into its precision oncology network.

Latest Market news:

The precision medicine market is experiencing rapid expansion, with North America remaining the leading region and Asia-Pacific emerging as the fastest-growing area due to increased national genomics projects and AI adoption in healthcare.

AI-driven technologies are increasingly integrated into precision medicine, with healthcare providers adopting machine learning for improved patient stratification, drug matching, and personalized care solutions.

SOPHiA GENETICS launched the SOPHiA DDMTM Digital Twins platform in October 2025, utilizing AI-powered digital twin modeling to enhance oncology diagnostics and support clinicians with real-time decision-making tools.

Ongoing investments and partnerships focus on advancing biomarker discovery, next-generation sequencing, and real-world data analytics, particularly for oncology, rare diseases, and chronic disease management.

Caris Life Sciences has expanded its multi-omics diagnostics and data platform, which is driving innovation in the use of integrated health data for personalized treatments

key Players:-

F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Pfizer Inc., GSK plc, Biogen, Bristol-Myers Squibb Company, Abbott, Merck & Co., Inc., and BGI, among others.

Growth Forecast Projected:

The Global Precision Medicine Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Precision Medicine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=precision-medicine-market?oppratik

Investments & Financial Developments

Kriya Therapeutics completed a USD 313 million fundraise to advance gene therapy programs.

Strand Therapeutics raised USD 153 million Series B, backed by Amgen and Eli Lilly, to develop programmable mRNA cancer drugs.

Wugen Inc. secured USD 115 million to fund pivotal trials of allogeneic CAR-T therapies.

OrbiMed launched a USD 1.86 billion Royalty & Credit Opportunities Fund V, aimed at non-dilutive healthcare financing.

Market segmentation:

By Technology: Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Others

By Application: Diagnostics, Therapeutics, Others

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Precision Medicine producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Precision Medicine revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/precision-medicine-market?oppratik

Product launches

In September 2025, a company launched a tissue-informed whole genome sequencing test aimed at improving detection of minimal residual disease in cancer patients.

The same month, another firm unveiled a drug assessment platform using deep artificial intelligence for precision drug development.

Also in September 2025, a 3D perfusion bioreactor system was introduced to replicate human physiological conditions for more accurate in vitro testing.

Additionally, a personalized dosing platform for optimizing treatment of metabolic diseases was launched, supporting tailored therapy regimens.

FAQ's

Q1: What is the current size of the Precision Medicine Market?

A: The Precision Medicine Market stood at US$98.87 billion in 2024 and is set to experience remarkable growth, reaching US$329.73 billion by 2033

Q2: How fast is the Precision Medicine Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 14.8%from 2025 to 2033

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.